Index

A
Accelerated partial breast irradiation (APBI)
   acute and long-term reaction, 304, 305
BCT (see Breast conserving therapy (BCT))
   clinical target volume, 307, 308
CT scans and MRI images, 305, 306
CyberKnife, 303, 308–310
EBRT, 296–298
ELIOT, 302
HDR, 296–299
IMRT, 295, 310
interstitial brachytherapy, 299, 300, 302
intra-operative radiotherapy, 296–298
LDR, 296–299
lumpectomy, 295, 299, 302, 308
patient outcome, 308, 310
patient selection, 304
quality of life, 294, 311
respiratory motion, 301
3D-CRT, 295, 302, 310
treatment planning
   clinical target volume, 307, 308
   CT scans and MRI images, 305, 306
   fiducial, 305–307
   NSABP/RTOG study, 307
   PTV, 307, 308
Active breathing control (ABC), 24, 165
American Cancer Society, 225
American Urologic Association, 226
Anisotropic analytic algorithm (AAA), 91
Arteriovenous malformations (AVMs), 116–117

B
Biologically effective dose (BED)
   biological impact, 71
   ‘ceiling’ dose, 71
   conventional treatment, 72
   linear radiosensitivity coefficient, 71
   LRNT, 73
   Nd, 71–72
   prediction model, 72
   reference value, 72
   single-fraction treatment, 72
Biologically equivalent dose (BED), 318
Breast conserving therapy (BCT)
   advantage, 294
   compatibility of, 294
   disadvantage, 294
   radiotherapy role, 295–296
Breath-hold methods, 133, 135

C
Chronic myeloid leukemia (CML), 233
CI. See Conformality index (CI)
Cleveland Clinic, 228
Clinical target volume (CTV), 75, 129, 198–199, 257, 273, 307, 308, 320
Clinical tumor volume (CTV), 99
   lung tumors, 129
   spinal radiosurgery, 118, 119
Conformality index (CI), 89
Cosmesis, 299, 301, 310, 311
CyberKnife planning, 88
CyberKnife Robotic Radiosurgery system, 187
CyberKnife Synchrony software, 23
CyberKnife® system, 37, 38
D
Data acquisition
   Cyberknife systems, 48
detector choice, 48–50
gantry angle tilt, 48, 52
mMLC type system, 48
non-scanned data, 50
output factors, 48, 50
scanned data, 47–48
scanning arm tilt, 48, 51
standard farmer type chamber, 48
Deep inspiration breath-hold technique (DIBH), 133
Delivery quality assurance (DQA) method
   end-to-end QA method, 102
trigeminal neuralgia, 103, 104
typical SRS plan, 102, 103
Disease-free survival (DFS), 268
Dosimetry
   intra-fraction imaging, 102
patient-specific measurements, 102–103
reference, 101
relative dosimetry, 101–102
scatter and leakage dose, 102
DQA. See Delivery quality assurance (DQA) method

E
Electronic portal imaging (EPID), 29
Electron Intraoperative radiotherapy (ELIOT), 302
Elekta Axesse™, 36
Erasmus MC—Daniel den Hoed Cancer Center, 254
ExacTrac® Robotic 6D Couch, 36
External beam radiation therapy (EBRT), 296–298, 316, 317

F
Four-dimensional (4D)
   respiration-correlated CT, 31
Frame-based Gamma Knife® technology, 285

G
Gross target volume (GTV), 198, 256, 273
Gross tumor volume (GTV), 129, 130, 167–168, 230, 257, 320
GyroKnife system, 39, 40

H
HCC. See Hepatocellular carcinoma (HCC)
Head and neck cancer (HNC)
   acute radiation toxicity, 265, 266
   alcohol and tobacco, 254
   clinical target volume, 257
   Cyberknife, 256, 263
diagnostic investigations, 256
dysphagia and xerostomia, 255
efficacy and safety, 263
Erasmus MC
   OPC, 257, 259, 260, 262
organ preservation protocol, 261–263
gross target volume, 256–257
HPV, 254
hyperthermia, 275
image-guided radiotherapy systems, 256
late radiation toxicity, 265, 267
multivariate regression analysis, 265, 266
organs at risk (OAR), 257–259
overall survival (OS) rates, 263
overview of, 263–264
PORT, 254–255
prevalence, 253–254
recurrent (see Recurrent head and neck cancer)
squamous cell type origin, 254
SRT + HT treatment schedule, 264, 265
toxicity outcomes, 259–262
treatment sites, 263
Hepatocellular carcinoma (HCC)
dose-volume effect, 151
evidence, 151–154
high-precision radiotherapy, 151
percutaneous ablation, 150
RFA, 150
RILD, 150, 151
staging systems, 150, 151
surgical resection, 150
survival outcomes, 150
systemic chemotherapy, 150
TACE, 150
High dose fractions. See Linear-quadratic (LQ) model
HNC. See Head and neck cancer (HNC)
Human papillomavirus (HPV), 254
Hyperthermia (HT), 275
Hypoxic cell sensitising drugs (HCS), 80

I
Image-guided radiation therapy (IGRT), 55
Intensity modulated radiation therapy (IMRT), 87, 257, 295, 310, 317–318
Internal gross tumor volume (ITV), 129, 132–133
International Commission on Radiation Units and Measurements (ICRU), 256
Intra-hepatic cholangiocarcinoma (IHC), 149–151
ITV. See Internal gross tumor volume (ITV)

L
Laparoscopic partial nephrectomy (LPN), 227
Late-responding normal tissues (LRNTs), 71
Linear energy transfer (LET), 81
Linear-quadratic (LQ) model
\( \alpha/\beta \) ratios, 68
‘avalanche’ effect, 68
BED, 71–72
clinical factors
co-morbidity, 81
high linear energy transfer, 81
RBE issues, 81–82
downward curvature effect, 68
fractional cell survival, 68–70
hot-spots tissue, 75–76
implications, 82–84
linear scale and logarithmic scale, 70
LQ-type formulations, 70
quantitative evaluation, 70
radiobiological factors
cell cycle re-assortment, 80
extended fraction times, 79–80
normal tissue volume effects, 80–81
re-oxygenation, 80
repair, 78–79
tumour repopulation, 77–78
tumour volume effects, 81
straightening-out effect, 73–75
Liver
acute toxicity, 175
CBCT, 174
CRC metastases
autopsy study, 154
chemotherapy, 154
Child-Pugh score, 161
clinical assessment, 162
exclusion criteria, 162
local control rates, 155
patient selection criteria, 161
prospective studies, 155, 158–160
retrospective studies, 155–157
site, 155
surgical data, 154–155
survival rates, 155
thermal destruction, 154
follow up, 176
fractionation, 169, 172–174
HCC
dose-volume effect, 151
evidence, 151–154
high-precision radiotherapy, 151
RFA, 150
RILD, 150, 151
staging systems, 150, 151
surgical resection and percutaneous ablation, 150
survival outcomes, 150
systemic chemotherapy, 150
TACE, 150
IHC, 149–151
late toxicity, 175–176
radiotherapy (see Radiotherapy treatment planning)
treatment planning
CT scan, 167
GTV, 167–168
MRI, 167
OAR, 168–169
target volume, 169–174
treatment response, 176
Liver metastases
abdominal compression, 8
active breathing control, 8
conventional radiotherapy technique, 7
Elekta stereotactic body frame, 7
radiofrequency ablation, 7
Lung tumors
breath-hold methods, 133, 135
central tumors
high and low dose fractions, 139–140
local control rate, 140
OAR injury, 139
pericardium/mediastinal structures, 140
risk-adapted treatment, 141
clinical outcome, 141–142
3D CRT, 128
dose constraints and prescription, 136, 137
dose distribution, 128
forced shallow breathing, 133–135
GTV and CTV, 129
ITV, 128–129, 132–133
NSCLC, 128
Lung tumors (cont.)
  peripheral tumors
    BED, 139
  cardiovascular and pulmonary
diseases, 139, 140
  local control, 139
  single fraction, 137
  T1 vs. T2 tumors, 138
real-time tumor tracking
correlation model, 131–132
  CT scan, 131
  CyberKnife, 130, 132
  LEDs, 130
  X-ray imaging, 130
respiratory gating methods, 135–136
simulation, 136
toxicity
  central lesions, 143
  peripheral lesions, 142–143
  quality of life, 143–144
treatment planning, 136

M
Micro multi-leaf collimators (mMLC), 47, 48

N
National Surgical Adjuvant Breast and Bowel
Project (NSABP), 294
Nephron-sparing surgery, 226–227
Non-small cell lung cancer (NSCLC)
  Cyberknife, 6
  RTOG, 6
  safe and effective treatmen, 6
  survival rate, 5
Non-surgical nephron sparing surgery, 227

O
OAR. See Organ at risk (OAR)
Oligometastasis
  adrenal metastases, 237, 242
  de novo oligometastases, 234
  fiducials, 246
  liver metastases
    clinical outcomes, 237, 239–240
    RILD, 246
  local recurrence/progression, 6–7
  lung metastases
    clinical outcomes, 237, 238
    complications, 247
  lymph node metastases, 237, 241
  mixed oligometastatic sites, 237, 243–244
  natural history, 234–235
patient outcomes, 237
pre-SBRT evaluation, 245
radiotherapy, 235
surgical precedence, 235
systemic therapy, 245
toxicity, 236
Organ at risk (OAR), 89, 168–169
Organ preservation protocol, 261–263
Oropharyngeal cancer (OPC), 257, 259, 260, 262

P
Pancreatic cancer
  clinical outcomes, 188, 190
  dose prescription, 185–187
  incidence, 183
  indication, 191
  patient selection, 184
  patients survival rate, 184
  patient work-up, 184–185
  systemic chemotherapy, 187–188
  toxicity, 188–190
  treatment delivery, 187
  treatment planning, 185
  tumor control, 189, 190
Planning organ at risk (PRV), 99
Planning target volume (PTV), 185, 307, 308, 310, 311, 320
spinal radiosurgery, 118–119
treatment planning, 89, 90
Postoperative radiation therapy (PORT), 254–255
Primary liver tumours, 8
Prostate cancer
  fl exprone position, 11
  hypofractionation
    α/β [alpha/beta] ratio, 196, 197
    biologic potency, 198
    concept of, 196
    CyberKnife device, 197
    high dose rate (HDR)
      brachytherapy, 197
      patient history, 198–201
    incidence, 196
    monotherapy
      biochemical disease-free
        survival rate, 204
      crude biochemical disease-free
        survival rate, 201–202
      CyberKnife delivered SBRT, 201, 202
      gantry-based prostate SBRT, 203, 205
      HDR brachytherapy, 202–203
      Phoenix definition, 204
      planning target volume, 201
neoadjuvant/adjuvant androgen deprivation therapy, 220, 221
“non-escalated” approaches, 208
phase II clinical trial, 11
planning method, 11
prevalence, 196
radiobiology potency considerations
intraprostatic dose, 205, 206
periprostatic dose, 205–207
relapsed and/or metastatic cases
“curative intent” salvage strategies, 209
IRB-approved clinical trial, 209
post-RT prostate recurrence, 210
skeletal radiotherapy, 210
treatment techniques and strategies
biologic factors, 215–216
CT-based vs. MRI, 211–212
image-guidance methodology, 212–215
monotherapy vs. combined modality therapy, 210–211
technical factors, 216–218
Prostate CyberKnife SBRT, 198, 199
PTV. See Planning target volume (PTV)

Q
Quality assurance (QA), 35–36
CT-based IGRT systems, 55
dosimetric QA
beam stability test, 57
dose-to-end test, 57–58
patient specific measurement, 58
validation measurement vs. treatment planning output, 56–57
IGRT system accuracy, 56
on-line imaging systems, 53–55
residual correction error method, 55
target localization accuracy, 53
“Winston-Lutz” test, 53

R
Radiation induced liver disease (RILD), 68, 246
Radiation myelopathy, 121
Radiation therapy oncology group (RTOG), 307
Radiofrequency ablation (RFA), 150
Radiotherapy treatment planning
axial, sagittal and coronal sections, 169, 170
delineation
CT scan, 167
CTV, 167–168
GTV, 167
immobilisation, 166–167
MRI, 167
OAR, 168–169
patient positioning, 166–167
PTV, 167–168
fiducial placement, 164
motion tracking, 166
patient positioning, 164, 166–167
pre-treatment imaging, 165
respiratory motion, 166
vs. SBRT delivery systems, 162, 163
tumour motion
ABC technique, 165
abdominal compression, 165
managing respiratory motion, 166
passive respiratory gating, 166
real time tracking, 166
VMAT, 169–174
Real-time Position Management™ (RPM) system, 31
Recurrent head and neck cancer
acute mucositis, 272
brachytherapy, 268
complications, 268–270
DFS, 268
IMRT, 273–274
multivariate analysis, 271
optimal dose fractionation, 275
phase I dose-escalation clinical trial, 271
re-irradiation, 272
salvage surgery, 267
stereotactic radiosurgery, 270–271
Reference dosimetry method, 101
Relative biological effect (RBE), 81–82
Renal cancer
CyberKnife, 228–229
nephron-sparing surgery, 226–227
non-surgical nephron sparing surgery, 227
patient selection, 229
post treatment care, 231
prevalence, 225
radiation therapy, 227–228
“radioresistant” tumor, 225
radiosurgery, 225–226
toxicity, 230
treatment planning and delivery CyberKnife™ system, 230, 231
GTV and CTV, 230
organ at risk, 230
reproducible immobilization, 229
Renal cell carcinoma (RCC), 10.
See also Renal cancer
Respiratory gating methods, 135–136
Sexual Health Inventory Matrix (SHIM) score, 198
Siemens Primatom™, 36
Soft tissue sarcomas (STS)
BED, 318
cerebral metastases, 319
clinical assessment, 322
EBRT, 316, 317
high-dose photon irradiation, 317
IMRT, 317–318
local control rate, 317
metastatic sarcoma, 318–319
patient selection, 319–320
radioresistant, 315
role of, 322
toxicity, 322
treatment planning, 320–321
Spinal radiosurgery
benign intracranial tumors, 113
CTV, 118, 119
CyberKnife, 115, 116, 120
diagnostic images, 117
dose fractionation, 120, 121
dose-volume constraints, 119, 120
epidural spinal cord compression, 113
follow up, 115, 122
GTV, 118, 119
metastatic melanoma, 110, 111
patient history, 109–110
patient selection
ASTRO guidelines, 115, 117
contraindications, 116, 117
indications, 116
peripheral nerve sheath tumor, 110, 112
PTV, 118–119
series selection, 113, 114
simulation, 118
TomoTherapy, 115, 116
toxicity, 121–122
treatment planning, 119–120
vertebral level, 118, 119
Stereotactic body radiotherapy (SBRT)
abdominal compression, 21
APBI (see Accelerated partial breast irradiation (APBI))
characteristics, 20
clinical evolution, 22–24
commercially available systems
CyberKnife® system, 37, 38
Elekta Axesse™, 36
ExacTrac® Robotic 6D Couch, 36
GyroKnife system, 39, 40
Siemens Primatom™, 36
tomotherapy, 37, 38
Varian's TrueBeam STx system, 36–37
Vero SBRT system, 36, 39
ViewRay, 39–40
commissioning system
beam data, 47
Cyberknife systems, 48
detector choice, 48–50
gantry angle tilt, 48, 52
mMLC type system, 48
non-scanned data, 50
output factors, 48, 50
scanned data, 47–48
scanning arm tilt, 48, 51
standard farmer type chamber, 48
TPS, 52
CT/MRI simulator, 23
Cyberknife, 4
evaluation, 19
features, 27
fractionation and radiobiology, 3
Gamma Knife treatments, 20
history, 2–3
HNC (see Head and neck cancer (HNC))
indications
kidney, 10
liver metastases, 7–8
lung oligometastases, 6–7
NSCLC, 5–6
pancreas, 8–9
primary liver tumours, 8
primary spinal tumors, 12–13
prostate, 10–11
vertebral metastases, 11–12
locations, 24
LQ model (see Linear-quadratic (LQ) model)
micro-multi leaf collimator, 4
Novalis TX, 4
oligometastasis (see Oligometastasis)
pancreatic cancer (see Pancreatic cancer)
prostate cancer (see Prostate cancer)
QA (see Quality assurance (QA))
radiobiological rationale, 24–25
Renal cancer (see Renal cancer)
respiratory motion, 4–5
STS (see Soft tissue sarcomas (STS))
system components and requirements
beam characteristics, 33–34
CT, 29, 32
4D CT, 31
2D radiography and CT localization systems, 29
dual/multiple KV image systems, 29
Index

EPID, 29
18F-fluorodeoxyglucose (18FDG), 32
gating techniques, 31
MRI, 30, 32
optical systems, 31
patient immobilization, 28–29
QA process, 35–36
radiofrequency-based tracking system, 30
treatment planning, 34–35
ultrasound devices, 30
TomoTherapy System, 4
TPS (see Treatment planning system (TPS))
treatment delivery, 23
treatment planning
AVM, 92
conventional IMRT, 87–88
CT scan, 91–92
dose calculation algorithms and heterogeneities, 90–91
DQA method, 102–104
Gamma Knife treatment, 88
high CI, 89
high MU-to-dose ratio, 88
homogeneous vs. heterogeneous, 88
impact of planning errors, 103–104
liver, 166–174
lung, 91
metallic stents, 92
non-isocentric techniques, 89
OAR sparing, 89
peripheral dose, 93
PTV, 89, 90
respiratory motion and deformation
respiratory motion and deformation: imaging, 98–99
respiratory motion and deformation: margin determination, 99–100
respiratory motion and deformation: relative motion, 99
RTOG, 92
skin dose, 92–93
TACE, 92
treatment delivery time, 89–90
tumor dose and OAR constraints
brain, 95
liver, 97, 98
lung, 96
pancreas, 97
prostate, 97–98
spine, 95–96
Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 203, 204, 216
Stereotactic radiosurgery (SRS)
brain, 95
CARO recommendations, 96
commercially available systems, 36
dose gradients, 102, 103
image-guided delivery, 89
patient selection, 115
planning, 88–89
quality assurance, 52–55
spine (see Spinal radiosurgery) treatments, 90
Synchrony™ Respiratory Tracking system, 31

T
Tamoxifen, 308
Three-dimensional conformal radiotherapy (3D-CRT), 295
TomoTherapy system, 4, 37, 38
Treatment planning system (TPS)
AAPM Task Group 101 Report, 61, 63
anatomical/clinical patient set up, 59
commissioning, 52
conformality index, 61, 62
3-D coordinate system, 59
dose heterogeneity, 60, 61
motion management, 59, 60
prescription normalization, 60, 62
simulation, 59
target delineation, 59

U
Uveal melanoma
Cyberknife patients, 286, 287
dose de-escalation, 290
fundoscopy image, 286, 289
indications, 285
ophthalmic plaque radiotherapy, 284
prevalence, 284
radiation therapy, 284
radiosurgery treatment process, 285–286
retrobulbar anesthesia, 288, 290
robotic radiosurgery, 290
single-session radiosurgery, 285
T2 MRI sequence, 286, 288
visual preservation and eye retention, 290
V
Varian’s TrueBeam STx system, 36–37
Vero SBRT system, 36, 39
Vertebral compression fracture (VCF), 121–122
ViewRay, 39–40
“Virtual HDR®”, 202–203

VMAT. See Volume modulated arc therapy (VMAT)
Volume modulated arc therapy (VMAT), 89

W
Whole breast irradiation (WBI), 294
“Winston-Lutz” test, 53